A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer
Abstract Objective The solute carrier family 25 member 1 (SLC25A1) is currently the only known human transporter for citrate in the mitochondrial membrane. However, its role in cancer development remains to be elucidated. We aim to analyze the expression profile, prognostic value, potential immunolo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2023-11-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-023-00830-z |
| _version_ | 1797452171795496960 |
|---|---|
| author | Xin You Lingling Huang Ouxiang Huang Yujie Deng Xi Shi |
| author_facet | Xin You Lingling Huang Ouxiang Huang Yujie Deng Xi Shi |
| author_sort | Xin You |
| collection | DOAJ |
| description | Abstract Objective The solute carrier family 25 member 1 (SLC25A1) is currently the only known human transporter for citrate in the mitochondrial membrane. However, its role in cancer development remains to be elucidated. We aim to analyze the expression profile, prognostic value, potential immunological significance, and effect on tumor growth of SLC25A1 at a pan-cancer level. Methods Herein, the role of SLC25A1 in tumorigenesis and progression was investigated based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), GeneMANIA, STRING and Cancer Dependency Map Project (DepMap) database via online websites or the R software. The protein expression levels were validated in tissue microarrays, and the effects on tumor cell lines were accessed through MTS and colony formation assays. Results The expression of SLC25A1 increased in most cancers, and the upregulation of SLC25A1 in colon adenocarcinoma and lung adenocarcinoma was further confirmed by immunohistochemistry. Meanwhile, SLC25A1 was linked to clinical outcomes across multiple tumor types, particularly in lung adenocarcinoma, where its high expression predicted poor prognosis. Moreover, SLC25A1 was positively associated with MSI, TMB, and CD276 and tightly correlated with tumor-infiltrating immune cells. Furthermore, the knockout of SLC25A1 demonstrated inhibitory effects in most cancer cell lines in the DepMap project. Cellular experiments showed that SLC25A1 knockdown significantly reduced the proliferation of lung adenocarcinoma cells. Conclusions Our findings suggest the potential of SLC25A1 as a prognostic biomarker for cancers and a therapeutic target for precise antitumor strategy and cancer immunotherapy. |
| first_indexed | 2024-03-09T15:04:56Z |
| format | Article |
| id | doaj.art-6ae3c5048f70460e8761fa831b506990 |
| institution | Directory Open Access Journal |
| issn | 2730-6011 |
| language | English |
| last_indexed | 2024-03-09T15:04:56Z |
| publishDate | 2023-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj.art-6ae3c5048f70460e8761fa831b5069902023-11-26T13:43:29ZengSpringerDiscover Oncology2730-60112023-11-0114112110.1007/s12672-023-00830-zA comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancerXin You0Lingling Huang1Ouxiang Huang2Yujie Deng3Xi Shi4Department of Oncology, The First Affiliated Hospital of Fujian Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Fujian Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Fujian Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Fujian Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Fujian Medical UniversityAbstract Objective The solute carrier family 25 member 1 (SLC25A1) is currently the only known human transporter for citrate in the mitochondrial membrane. However, its role in cancer development remains to be elucidated. We aim to analyze the expression profile, prognostic value, potential immunological significance, and effect on tumor growth of SLC25A1 at a pan-cancer level. Methods Herein, the role of SLC25A1 in tumorigenesis and progression was investigated based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), GeneMANIA, STRING and Cancer Dependency Map Project (DepMap) database via online websites or the R software. The protein expression levels were validated in tissue microarrays, and the effects on tumor cell lines were accessed through MTS and colony formation assays. Results The expression of SLC25A1 increased in most cancers, and the upregulation of SLC25A1 in colon adenocarcinoma and lung adenocarcinoma was further confirmed by immunohistochemistry. Meanwhile, SLC25A1 was linked to clinical outcomes across multiple tumor types, particularly in lung adenocarcinoma, where its high expression predicted poor prognosis. Moreover, SLC25A1 was positively associated with MSI, TMB, and CD276 and tightly correlated with tumor-infiltrating immune cells. Furthermore, the knockout of SLC25A1 demonstrated inhibitory effects in most cancer cell lines in the DepMap project. Cellular experiments showed that SLC25A1 knockdown significantly reduced the proliferation of lung adenocarcinoma cells. Conclusions Our findings suggest the potential of SLC25A1 as a prognostic biomarker for cancers and a therapeutic target for precise antitumor strategy and cancer immunotherapy.https://doi.org/10.1007/s12672-023-00830-zSLC25A1Pan-cancerPrognosisTumor immunityTherapeutic target |
| spellingShingle | Xin You Lingling Huang Ouxiang Huang Yujie Deng Xi Shi A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer Discover Oncology SLC25A1 Pan-cancer Prognosis Tumor immunity Therapeutic target |
| title | A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer |
| title_full | A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer |
| title_fullStr | A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer |
| title_full_unstemmed | A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer |
| title_short | A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer |
| title_sort | comprehensive analysis of slc25a1 expression and its oncogenic role in pan cancer |
| topic | SLC25A1 Pan-cancer Prognosis Tumor immunity Therapeutic target |
| url | https://doi.org/10.1007/s12672-023-00830-z |
| work_keys_str_mv | AT xinyou acomprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT linglinghuang acomprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT ouxianghuang acomprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT yujiedeng acomprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT xishi acomprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT xinyou comprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT linglinghuang comprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT ouxianghuang comprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT yujiedeng comprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer AT xishi comprehensiveanalysisofslc25a1expressionanditsoncogenicroleinpancancer |